26
|
Comito T, Franzese C, Clerici E, Navarria P, D'Agostino G, Carrara S, Rimassa L, Tomatis S, Zerbi A, Scorsetti M. EP-1430 Can SBRT improve the prognosis of unresectable pancreatic cancer? Clinical results on 106 patients. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31850-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
27
|
Gkika E, Brunner T, Abbasi-Senger N, Alheit H, Baus W, Blanck O, Gerum S, Guckenberger M, Habermehl D, Ostheimer C, Riesterer O, Tamihardja J, Pinato D, Rimassa L, Pressiani T, Schultheiss M, Sharma R, Burlone M, Pirisi M, Kudo M, Park J, Neumann-Haefelin C, Grosu A, Thimme R, Bettinger D. PO-0811 SBRT compared to sorafenib in locally advanced hepatocellular carcinoma: a propensity score analysis. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31231-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
28
|
Yau T, Merle P, Rimassa L, Ryoo BY, Cicin I, Harris W, Banu E, Sarker D, Tan B, van Vlierberghe H, Sen S, Love C, Cheng AL, Meyer T, Kelley R, Abou-Alfa G. Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy432] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
29
|
Kelley R, El-Khoueiry A, Meyer T, Rimassa L, Merle P, Chan S, Tran A, Parnis F, Tam V, Cattan S, Markby D, Clary D, Cheng AL, Abou-Alfa G. Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.085] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
|
30
|
Morano F, Corallo S, Di Bartolomeo M, Lonardi S, Cremolini C, Rimassa L, Sartore Bianchi A, Murialdo R, Zaniboni A, Adamo V, Tomasello G, Tampellini M, Fanchini L, Schirripa M, Clavarezza M, Petrelli F, Longarini R, Cinieri S, de Braud F, Pietrantonio F. Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus pan or single-agent pan: Translational analyses of the VALENTINO study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Barni S, Rosati G, Zagonel V, Pella N, Banzi M, Zampino M, Di Bartolomeo M, Rimassa L, Marchetti P, Maiello E, Artioli F, Ferrari D, Labianca R, Bidoli P, Zaniboni A, Sobrero A, Iaffaioli V, de Placido S, Frassineti L, Galli F, Petrelli F. Thromboembolic risk and survival with Khorana score in resected colorectal cancer patients: Subgroup analysis from the adjuvant TOSCA trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Petrelli F, Rosati G, Banzi M, Zampino M, Pella N, Di Bartolomeo M, Maiello E, Bidoli P, Ferrari D, Rimassa L, Labianca R, Scartozzi M, Lonardi S, de Placido S, Zaniboni A, Sobrero A, Frassineti L, Silvestris N, Corsi D, Galli F, Barni S. Prognostic value of neutrophil-lymphocite ratio in resected high risk colorectal cancer: An analysis of adjuvant TOSCA trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
33
|
Merle P, Rimassa L, Ryoo B, Cicin I, Harris W, Banu E, Sarker D, Tan B, Van Vlierberghe H, Sen S, Love C, Cheng A, Meyer T, Kelley R, Abou-Alfa G. Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy149.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
|
34
|
Cheng A, Abou-Alfa G, Ren Z, Assenat E, Cubillo A, Pluntke S, Rimassa L, Ross P, Wyrwicz L, Hou J, Li C, Wu J, Ducreux M. Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma - Trial in progress. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
35
|
Ziranu P, Demurtas L, Puzzoni M, Loupakis F, Daniele B, Rimassa L, Bilancia D, Lonardi S, Avallone A, Pella N, Ferrari D, Frassineti L, Beretta G, Zaniboni A, Santoro A, Zampino M, Sarobba M, Zagonel V, Barni S, Palmieri G, Labianca R, Cascinu S, Scartozzi M. The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.290] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Bajetta E, Rimassa L, Carnaghi C, Del Vecchio M, Celio L, Cassata A. Preliminary Experience with High-Dose Cisplatin, Reduced Glutathione and Natural Interferon-α in Dacarbazine-Resistant Malignant Melanoma. TUMORI JOURNAL 2018; 84:48-51. [PMID: 9619714 DOI: 10.1177/030089169808400110] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Aims and background The incidence of malignant melanoma is rapidly increasing in many countries, and when this disease has reached advanced stages, standard therapies have little impact. Dacarbazine (DTIC) is the most effective chemotherapeutic agent with an overall response rate of 20-25%, but durable responses are uncommon. Interesting results with the use of cisplatin (CDDP) have been reported in DTIC-resistant melanoma. Moreover, malignant melanoma is an immunogenic tumor and a potential target for biological response modifier (BRM) therapies. The aim of the present study was to evaluate the efficacy and tolerability of a chemo-immunotherapeutic regimen including high-dose CDDP combined with glutathione (GSH) to limit platinum-related toxicity, and natural interferon-α (IFN-α) in patients with DTIC-resistant metastatic melanoma. Methods The treatment schedule included GSH 1,500 mg/m2 i.v. and CDDP 40 mg/m2 i.v. for 4 consecutive days every 3 weeks, with a maximum of 6 courses, and IFN-α 3 MIU i.m. 3 times a week, continuative for a maximum of 12 months. Results Twelve patients were enrolled in this phase II trial. Accrual was stopped due to treatment-related toxicity. Ten patients were evaluable for response; there were 2 partial responses, lasting 5+ and 9+ months, respectively, and 2 cases of stable disease, lasting 3+ and 8+ months. None of these patients completed the therapeutic program due to treatment-related side effects. Conclusions This regimen seems to be only partially active in DTIC-resistant metastatic melanoma. Hematologic and non-hema-tologic (nausea and vomiting, peripheral neurotoxicity, and asthenia) side effects are significant and GSH is not effective in limiting CDDP-related neurotoxicity in pretreated patients. Therefore, there is no indication to employ this regimen as second-line treatment in metastatic melanoma and these disappointing results highlight the urgent need for new therapeutic approaches.
Collapse
|
37
|
Baretti M, Personeni N, Destro A, Santoro A, Rimassa L. Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity? Cancer Biol Ther 2018; 19:659-663. [PMID: 29580164 DOI: 10.1080/15384047.2018.1450117] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Tumors represent a dynamic system where the genomic plasticity permits to adapt to the perturbation induced by environmental pressures, supporting the importance of longitudinal tumor sampling strategies to deciphering the temporal acquisition of driver event that could impact treatment outcome. We describe the case of a metastatic colorectal cancer (mCRC) patient, RAS wild-type, who responded to anti-EGFR therapy and underwent liver surgery, revealing a KRAS mutations in the metastatic lesion, not detectable prior to initiation of therapy in the colonic biopsy. After liver surgery, the patient received chemotherapy alone, then underwent left colectomy and the final pathological report confirmed the KRAS wild-type status. We can speculate the existence of two distinct populations of KRAS wild-type and mutant CRC cells sharing the same genetic origin. The anti-EGFR treatment represented a selective pressure which allowed the selection of KRAS mutant subclones. The prognostic and /or predictive role of intratumor heterogeneity has not been assessed prospectively. Our case report is of clinical relevance because patients with mCRC who respond to anti-EGFR antibodies often develop resistance within several months of initiating therapy, thus outlining the importance to better ascertain the molecular landscape of tumors to design better therapeutic strategies.
Collapse
|
38
|
Pietrantonio F, Miceli R, Rimassa L, Lonardi S, Aprile G, Mennitto A, Marmorino F, Bozzarelli S, Antonuzzo L, Tamburini E, Morano F, Rossini D, Battaglin F, Baretti M, Berenato R, Formica V, Mosconi S, Petrelli F, Ghidini M, Loupakis F, Spada D, Cinieri S, Beretta G, Falcone A, de Braud F, Cremolini C. Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Ann Oncol 2017; 28:555-561. [PMID: 27864220 DOI: 10.1093/annonc/mdw627] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Background Regorafenib and TAS-102 have recently demonstrated statistically significant survival gains in patients with refractory metastatic colorectal cancer (mCRC). Life expectancy ≥12 weeks was an inclusion criterion in registrative trials, and the identification of proper clinical selection tools for the daily use of these drugs in heavily pre-treated patients is needed to improve the cost-benefit ratio. We aimed at building a nomogram able to predict death probability within 12 weeks from the date of assessment of refractory mCRC. Patients and methods Four hundred eleven refractory mCRC patients with ECOG performance status (PS) ≤2 receiving regorafenib, TAS-102 or other treatments were used as developing set. Putative prognostic variables were selected using a random forest model and included in a binary logistic model from which the nomogram was developed. The nomogram was externally validated and its performance was evaluated by examining calibration (how close predictions were to the actual outcome) and discriminative ability (Harrell C index) both on developing (internal validation) and validating (external validation) sets. Results Four variables were selected and included in the nomogram: PS (P < 0.0001), primary tumor resection (P = 0.027), LDH value (P = 0.0001) and peritoneal involvement (P = 0.081). In the developing set, the nomogram discriminative ability was high (C = 0.778), and was confirmed in the validating set (C = 0.778), where the overall outcome was better as a consequence of the enrichment in patients receiving regorafenib or TAS-102 (46% versus 34%; P < 0.0001). Conclusions Our nomogram may be a useful tool to predict the probability of death within 12 weeks in patients with refractory mCRC. Based on four easy-to-collect variables, the 'Colon Life' nomogram and free app for smartphones may improve mCRC patients' selection for later-line therapies and assist researchers for the enrollment in clinical trials in this setting.
Collapse
|
39
|
Lonardi S, Sobrero A, Rosati G, Di Bartolomeo M, Ronzoni M, Aprile G, Massida B, Scartozzi M, Banzi M, Zampino MG, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Barni S, Zagonel V, Maiello E, Rulli E, Labianca R. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. Ann Oncol 2017; 28:3110. [PMID: 28327986 DOI: 10.1093/annonc/mdx021] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
40
|
Zaniboni A, Lonardi S, Labianca R, Di Bartolomeo M, Rosati G, Ronzoni M, Pella N, Banzi M, Zampino M, Pasini F, Marchetti P, Rimassa L, Maiello E, Bidoli P, Cinieri S, Barni S, Ciuffreda L, Beretta G, Frontini L, Rulli E, Sobrero A. FOLFOX4/XELOX in stage II–III colon cancer: early survival data of the Italian Three Or Six Colon Adjuvant (TOSCA) trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx421] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Fanotto V, Uccello M, Fornaro L, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Peverelli G, Battaglin F, Avallone A, Scartozzi M, Cinieri S, Melisi D, Antonuzzo L, Pellegrino A, Gerratana L, Aprile G. Second-line treatment efficacy in elderly vs. non-elderly advanced gastric cancer patients: an Italian multicentre real-world study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx425.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Di Bartolomeo M, Rosato G, Banzi M, Pella N, Zampino M, Rimassa L, Maiello E, Marchetti P, Lonardi S, Labianca R, Zaniboni A, Sobrero A, Ferrari D, Bidoli P, Iaffaioli V, De Placido S, Frassineti L, Frustaci S, Nicolini M, Vernieri C, Galli F. Metformin and risk recurrence in resected stage II/III colon cancer (CC) patients (pts): subgroup analysis from the TOSCA trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx422.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
43
|
Labianca R, Lonardi S, Rosati G, Di Bartolomeo M, Ronzoni M, Pella N, Scartozzi M, Banzi M, Zampino M, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Barni S, Zagonel V, Maiello E, Rulli E, Sobrero A. FOLFOX4/XELOX in stage II–III colon cancer: Efficacy and safety results of the Italian Three Or Six Colon Adjuvant (TOSCA) trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Comito T, Cozzi L, Clerici E, Franzese C, Tozzi A, Iftode C, Navarria P, D’Agostino G, Rimassa L, Carnaghi C, Personeni N, Tronconi MC, De Rose F, Franceschini D, Ascolese AM, Fogliata A, Tomatis S, Santoro A, Zerbi A, Scorsetti M. Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study. Technol Cancer Res Treat 2017; 16:295-301. [PMID: 27311310 PMCID: PMC5616043 DOI: 10.1177/1533034616650778] [Citation(s) in RCA: 67] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2016] [Revised: 03/14/2016] [Accepted: 04/22/2016] [Indexed: 12/11/2022] Open
Abstract
PURPOSE To assess the efficacy of stereotactic body radiotherapy in patients with unresectable locally advanced pancreatic cancer. MATERIALS AND METHODS All patients received a prescription dose of 45 Gy in 6 fractions. Primary end point was freedom from local progression. Secondary end points were overall survival, progression-free survival, and toxicity. Actuarial survival analysis and univariate or multivariate analysis were investigated. RESULTS Forty-five patients were enrolled in a phase 2 trial. Median follow-up was 13.5 months. Freedom from local progression was 90% at 2 years. On univariate ( P < .03) and multivariate analyses ( P < .001), lesion size was statistically significant for freedom from local progression. Median progression-free survival and overall survival were 8 and 13 months, respectively. On multivariate analysis, tumor size ( P < .001) and freedom from local progression ( P < .002) were significantly correlated with overall survival. Thirty-two (71%) patients with locally advanced pancreatic cancer received chemotherapy before stereotactic body radiotherapy. Median overall survival from diagnosis was 19 months. Multivariate analysis showed that freedom from local progression ( P < .035), tumor diameter ( P < .002), and computed tomography before stereotactic body radiotherapy ( P < .001) were significantly correlated with overall survival from diagnosis. CONCLUSION Stereotactic body radiotherapy is a safe and effective treatment for patients with locally advanced pancreatic cancer with no G3 toxicity or greater and could be a promising therapeutic option in multimodality treatment regimen.
Collapse
|
45
|
Ghidini M, Cascione L, Lampis A, Pandolfo R, Carotenuto P, Trevisani F, Hahne J, Zito D, Guzzardo V, Zerbi A, Torzilli G, Roncalli M, Rimassa L, Santoro A, Fassan M, Valeri N, Braconi C. Prognostic value of the immune-related transcriptome in biliary tract cancers. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.86] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
46
|
Baretti M, Personeni N, Giordano L, Tronconi M, Pressiani T, Bozzarelli S, Rimassa L, Santoro A. Evaluation of Charlson comorbidity index as predictor of survival in stage II-III colorectal cancer patients treated with surgery and neoadjuvant/adjuvant chemotherapy: A single Institution observational study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
47
|
Bozzarelli S, Rimassa L, Giordano L, Sala S, Tronconi M, Baretti M, Personeni N, Pressiani T, Santoro A. Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.84] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Destro A, Russo C, Spaggiari P, Armenia S, Bellofiore E, Lorini M, Brambilla T, Cimino M, Spinelli A, Personeni N, Rimassa L, Di Tommaso L, Roncalli M. The impact of mass spectrometry multigenic platform on the management of metastatic colorectal patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
49
|
Personeni N, Giordano L, Abbadessa G, Porta C, Borbath I, Daniele B, Salvagni S, van Laethem JL, Van Vlierberghe H, Trojan J, Weiss A, Gasbarrini A, Shuster D, De Toni E, Lencioni M, Miles S, Lamar M, Schwartz B, Santoro A, Rimassa L. Prognostic value of the neutrophil-to-lymphocyte ratio in advanced hepatocellular carcinoma: An exploratory analysis from the ARQ197-215 study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.98] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
50
|
Baretti M, Giordano L, Rimassa L, Tronconi M, Pressiani T, Bozzarelli S, Personeni N, Santoro A. Prognostic impact of comorbidity in stage II-III colorectal cancer (CRC) patients treated with surgery and neoadjuvant/adjuvant chemotherapy: a single Institution observational study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|